| SEC Foi | FORM | 4 U | JNITED S | TATE | s s | ECUI | RITI | ES AN | DE | ХСНА | NGE | со | MM | SSION | | | | | |
|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------|----------------------------------------------------------|----------------------|---------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------|-------------------------------------------------------|--------|------------------------|------------------------------------------------------------------------------------------------|----------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------|--|
| | | | Washington, D.C. 20549 | | | | | | | | | | | OMB APPROVAL | | | | | |
| Section 16. Form 4 or Form 5 obligations may continue. See | | | | | | TOF CHANGES IN BENEFICIAL OWNE | | | | | | | | | Estim | Numbe ated av | erage burde | 3235-0287 en 0.5 | |
| Instruc | | | | | | | | e Investme | | | | 01193 | 4 | | <u> </u> | | | | |
| 1. Name and Address of Reporting Person [*] Leproust Emily M. | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>Twist Bioscience Corp</u> [TWST] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | wner | |
| (Last)(First)(Middle)C/O TWIST BIOSCIENCE CORPORATION681 GATEWAY BLVD. | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 04/01/2022 | | | | | | | | | X Officer (give title Other (specify below) below) President & CEO | | | | | |
| (Street) SOUTH SAN FRANCISCO CA 94080 | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (S | | (Zip) | | | | | | | | | | | | | | | | |
| Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | ansactio | n : ear) i | 2Curities Act 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. 4. Secur Transaction Dispose Code (Instr. 5) | | 4. Securit Disposed | of, or Benefi ities Acquired (A) d Of (D) (Instr. 3, 4 | | A) or | 5. Amou Securiti Benefic Owned | int of es ially Following | Form (D) or | vnership : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | | | Code V | | Amount (A) or (D) | | | Price | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | |
| Common Stock 04/01/ | | | | /01/202 | 2022 | | F | | 1,108(| 1) |) | \$52.9 | 1 193 | ,289 ⁽²⁾ | | D | | | |
| | | т | able II - Der (e.c | | | | | quired, [s, optio | | | | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Yea | , 4. Tran Code | saction (Instr | 5. Number on of | | 6. Date Exerci Expiration Dat (Month/Day/Ye | | able and | 7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4) | | curity | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | e Ownershi 5 Form: Ily Direct (D) or Indirec 1 (I) (Instr. 4 | Ownership | Beneficial Ownershi (Instr. 4) | |
| | | | | Code | V (A) | | (D) | Date Exercisab | | xpiration Date | Title | or Nu of | mber | | | | | | |
| Employee Stock Option (right to buy) | \$5.95 | | | | | | | (3) | 0 | 9/28/2025 | Commo Stock | n | 0 | | 24,360 | D | D | | |
| Employee | | | | | | | | (4) | 0 | 9/28/2027 | Commo Stock | n | 0 | | 150,87 | '9 | D | | |
| Stock Option (right to buy) | \$8.82 | | | | | | | | | | | | | | | | | | |
| Stock Option (right to | \$8.82 \$26.66 | | | | | | | (5) | 1 | 1/18/2028 | Commo Stock | n | 0 | | 266,53 | 9 | D | | |
| Stock Option (right to buy) Employee Stock Option (right to | | | | | | | | (5) | + | 0/23/2029 | | | 0 | | 266,53 | | D | | |

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e).

2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)

3. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

4. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

5. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

6. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date

Remarks:

/s/ William Solis, as Attorney-<u>04/01/</u>2022 in-Fact for Emily M. Leproust

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.